Gremse-IT GmbH is a software spin-off company that was founded and is still located in Aachen, a research and technology center in Germany. The main focus of the company is to develop innovative software for biomedical image data reconstruction, processing, and analysis.
In 2016, CEO Dr. Felix Gremse founded the company and successfully commercialized his first software product ‘Imalytics Preclinical’. ‘Imalytics Preclinical’ is mainly used for reconstruction, 3D-visualization, interactive segmentation, and analysis of preclinical image data sets. It can be applied to a wide variety of biomedical imaging studies such as cancer research, pharmacokinetical analyses, gastroenterological issues, or bone analysis. It supports data sets from several modalities such as CT, MRI, PET, SPECT, and optical imaging. Because the software is widely applicable, it was already used by several pharma companies (Roche, Bayer) as well as by research institutes. Thereby, it supported publishing over 130 scientific research articles (find them here: References).
Nowadays, Gremse-IT GmbH has been successfully established on the preclinical imaging market, cooperates with national and international companies and clients, and is continuously growing. Our interdisciplinary team consists of scientists with an excellent theoretical knowledge, but also with long years of practical experience in the field.
In our international team, we employ specialists of Computer Science, Programming, Image Analysis, System biology, Biology, and Medicine.
In addition to the development, commercialization, continuous improvement, training, and modification of our software Imalytics Preclinical, Gremse-IT GmbH also offers various services: